All posts in Announcements

03 Nov

Sale of Leydin Freyer to Vistra

In Announcements,M&A Advisory by SLM / November 3, 2021 / 0 Comments

SLM Corporate is pleased to announce that it acted as corporate adviser to the shareholders of Leydin Freyer, one of Australia’s leading corporate governance, accounting, and company secretarial services firms, on the sale of the business to leading global corporate services provider Vistra.  The sale followed an expression of interest campaign managed by SLM that attracted wide interest from both local and international corporate services firms.

Established in Melbourne more than 20 years ago, Leydin Freyer has forged a position as one of the leading providers of corporate governance and accounting services to ASX listed companies. The acquisition doubles the size of Vistra’s operations in Australia, expands its footprint into Melbourne, and further solidifies it’s global position as a leading corporate service provider and fund administrator.

SLM worked closely with Arnold Bloch Leibler who acted as legal adviser to the shareholders of Leydin Freyer.

For further information on this transaction, please contact Barry Lewin:

Mobile: +61 419 302 493


14 Oct

SLM advises ASX-listed global biopharmaceutical company Clinuvel Pharmaceuticals Limited (ASX: CUV) on updated remuneration arrangements for key executives

In Announcements,General News by SLM / October 14, 2019 / 0 Comments

SLM Corporate is pleased to announce that it has acted as independent adviser to the Remuneration Committee of the Board of Clinuvel Pharmaceuticals Limited in relation to the reasonableness of a proposed grant of performance rights to the Managing Director, and new remuneration arrangements for the Managing Director and Chief Financial Officer.

The proposed remuneration packages aimed to incentivise Clinuvel’s senior executives for achieving long term objectives, while awarding part of their incentives in Clinuvel equity in order to align their objectives and performance fully with the interests of the company’s shareholders.

SLM undertook benchmarking of the proposed packages against local and international comparable peers to Clinuvel, and also considered the experience of the executives and their track record of value creation for Clinuvel.  SLM’s findings and opinion as to the reasonableness of the proposed packages were presented to the Clinuvel Board’s Remuneration Committee.

Clinuvel is an ASX-listed global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.  The award of the proposed performance rights was conditional on the US Food and Drug Administration (“FDA”) approving Clinuvel’s lead drug, SCENESSE®, for distribution to EPP patients, to enter the US market.  This FDA approval was granted on 9th October 2019.

For further information on this matter please contact:

Barry Lewin

Managing Director

Ph: 03 9244 9644 or 0419 032493